ホーム › 多発性骨髄腫 › コロンビア特別区 › Washington
Washington、DCにおける多発性骨髄腫の臨床試験
Washingtonとその周辺地域（約30マイル以内）の拠点で、多発性骨髄腫に関する22件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies
被験者募集中第1相
- National Institutes of Health Clinical Center, Bethesda · 7マイル先
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
被験者募集中第3相
- Research Site, Washington D.C.
Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols
被験者募集中観察研究
- National Institutes of Health Clinical Center, Bethesda · 7マイル先
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
被験者募集中第2相
- National Institutes of Health Clinical Center, Bethesda · 7マイル先
Tissue Collection for Studies of Lymph Cancer
被験者募集中観察研究
- National Institutes of Health Clinical Center, Bethesda · 7マイル先
Adult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of Cytokine Release Syndrome (CRS)
被験者募集中第4相
- American Oncology Partners, PA dba The Center for Cancer and Blood Disorders, Bethesda · 7マイル先
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
被験者募集中第3相
- Center for Cancer and Blood Disorders, Bethesda · 7マイル先
18F-Fluciclovine PET/CT in Multiple Myeloma
被験者募集中第2相
- National Institutes of Health Clinical Center, Bethesda · 7マイル先
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
被験者募集中第3相
- American Oncology Partners, PA dba The Center for Cancer and Blood Disorders, Bethesda · 7マイル先
A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma
被験者募集中第2相
- Lombardi Comprehensive Cancer Center, Washington D.C.
Collection of Tissue Samples for Cancer Research
被験者募集中観察研究
- National Institutes of Health Clinical Center, Bethesda · 7マイル先
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
被験者募集中第3相
- Georgetown University Medical Center, Washington D.C.
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
被験者募集中第3相
- MedStar Washington Hospital Center MedStar Georgetown Cancer Institute, Washington D.C.
A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)
被験者募集中第2相
- GSK Investigational Site, Bethesda · 7マイル先
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
被験者募集中第3相
- Sibley Memorial Hospital, Washington D.C.
Mosaic Trial for Stem Cell Transplant Recipients
被験者募集中
- Georgetown University School of Medicine, Washington D.C.
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
被験者募集中第1相
- Maryland Oncology Hematology - Silver Spring /ID# 268562, Silver Spring · 7マイル先
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
被験者募集中第1/2相
- The Center for Cancer and Blood Disorders (CCBD), Bethesda · 7マイル先
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
被験者募集中第3相
- Sibley Memorial Hospital, Washington D.C.
Cancer Experience Registry (CER) for Cancer Patients and Caregivers
被験者募集中観察研究健康なボランティア歓迎
- Cancer Support Community Research & Training Institute, Washington D.C.
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
被験者募集中第3相
- GSK Investigational Site, Washington D.C.
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
被験者募集中第1/2相
- Georgetown Lombardi Comprehensive Cancer Center, Washington D.C.
他の都市における多発性骨髄腫の試験
- New York City, NY60件の研究
- Atlanta, GA42件の研究
- Boston, MA42件の研究
- Houston, TX38件の研究
- Durham, NC37件の研究
- Nashville, TN32件の研究
- Denver, CO27件の研究
- St. Louis, MO24件の研究
- Rochester, MN24件の研究
- Columbus, OH24件の研究
- Baldwin Park, CA23件の研究
- Chicago, IL22件の研究
Washingtonにおける他の研究
- がん（全種類）58件の研究
- 非小細胞肺癌55件の研究
- 乳がん46件の研究
- 転移性癌43件の研究
- 肺がん41件の研究
- 前立腺がん38件の研究
- 肥満症33件の研究
- 大腸癌29件の研究
- 心血管疾患28件の研究
- 膀胱癌26件の研究
- 急性骨髄性白血病24件の研究
- 卵巣がん23件の研究
ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。